#United States #Washington, D.C. #Cancer Research #Cizzle Bio #Prevent Cancer Foundation

Cizzle Bio Champions Cancer Survivors at Gala

On September 18, 2025, Cizzle Bio, Inc. proudly attended the Prevent Cancer Foundation®’s 40th Anniversary and Gala held at the National Building Museum in Washington, D.C. This biotechnology company is recognized for its pioneering work in creating advanced biomarker blood tests aimed at the early detection of lung and gastric cancers. By sponsoring this event, Cizzle Bio further demonstrated its dedication to promoting awareness, research, and access to innovative diagnostic solutions that can save lives.

The gala, themed "The United States Innovation Inspiration," attracted over 1,000 guests. It marked four decades of impact by the Prevent Cancer Foundation, which has tirelessly championed cancer prevention and early detection since its establishment in 1985. Through their guidance, the foundation has led significant research, educational campaigns, and screening programs aimed at empowering individuals to take proactive measures against cancer.

Among those representing Cizzle Bio was CEO Bill Behnke, a seasoned leader in healthcare innovation who emphasized the importance of collaboration among science, advocacy, and policy. He was accompanied by Dr. Ron Greeno, a key figure in clinical strategy, and Mary Jimenez, Executive Vice President, who focuses on advancing clinical research.

Bill Behnke expressed pride in Cizzle Bio’s role, stating, “Cizzle Bio was honored to join the Prevent Cancer Foundation® in celebrating 40 years of impact. This Gala highlights how science, advocacy, and policy can come together to save lives. We remain committed to working alongside clinicians, advocates, and policymakers to ensure that early detection is accessible to all patients.”

The event also recognized key advocates in cancer prevention. CNN Anchor Sara Sidner, a breast cancer survivor, hosted the evening. Among the honorees were Rep. Brian Fitzpatrick and Rep. Robin Kelly, both receiving the 2025 Cancer Champion award for their roles in enhancing access to preventative healthcare.

Cizzle Bio's commitment to innovation is exemplified through its development of two essential blood tests: CIZ1B, which is the first immunoassay designed specifically for early lung cancer detection, and DEX-G2, targeting early-stage gastric cancer with high accuracy. These tests are key components of the company's mission to establish early detection as the standard of care globally.

Collaboration was a focal point of the gala, with various leaders in the cancer care sector coming together for a common cause. Among them were Dr. Rebecca Kaltman from the Saville Cancer Screening and Prevention Center and Elizabeth Stark, a cancer genetic counselor. They highlighted the critical nature of partnerships in advancing cancer prevention and treatment.

Meriam Driss from the LUNGevity Foundation and representatives from Debbie's Dream Foundation also underscored their commitments to educating the public and increasing awareness around cancer screening. The connections formed at the gala exemplified the unity required in tackling a disease that affects millions.

Funds raised during the gala will further support the Prevent Cancer Foundation's programs, which include grants for research and community education campaigns, emphasizing that early detection leads to better outcomes for patients.

In conclusion, Cizzle Bio's sponsorship of the Prevent Cancer Foundation Gala aligns seamlessly with its mission to revolutionize cancer diagnostics. By pushing for innovations that facilitate early detection, Cizzle Bio not only champions cancer survivors but also stands as a vital player in the fight against this pervasive disease. With ongoing dedication, the company aims to collaborate with stakeholders across all facets of cancer care to ensure a future where cancer is not only detectable but preventable.